首页> 美国卫生研究院文献>Tumour Biology >Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials
【2h】

Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials

机译:抗EGFR单克隆抗体治疗的实体瘤患者的电解质紊乱评估:25项随机临床试验的汇总分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The role of anti-epithelial growth factor receptor monoclonal antibodies (anti-EGFR MoAbs) in treatment-related electrolyte disorders is still controversial. Therefore, we conducted a meta-analysis of published randomized controlled trials (RCTs) to evaluate the incidences and overall risks of all-grade and grade 3/4 electrolyte disorder events. We searched relevant clinical trials from PubMed, EMBASE, and Web of Knowledge databases, meeting proceedings of American Society of Clinical Oncology and the European Society of Medical Oncology, as well as ClinicalTrials.gov. Eligible studies included phases II, III, and IV RCTs. Statistical analysis was performed to calculate the summary incidence, relative risk (RR), and 95 % confidence intervals (CIs) using fixed effects or random effects models based on the heterogeneity of included studies. A total of 16,411 patients from 25 RCTs were included in this meta-analysis. The all-grade incidence of hypomagnesemia related to anti-EGFR MoAbs was 34.0 % (95 % CI 28.0–40.5 %), and that for hypokalemia and hypocalcemia were 14.5 % (95 % CI 8.2–24.4 %) and 16.8 % (95 % CI 14.2–19.7 %), respectively. Compared with chemotherapy alone in colorectal cancer, addition of cetuximab increased the risk of grade 3/4 hypomagnesemia and grade 3/4 hypokalemia with RRs of 7.14 (95 % CI 3.13–16.27, p < 0.001) and 2.19 (95 % CI 1.14–4.23, p = 0.019). Additionally, colorectal cancer patients in panitumumab cases were more vulnerable to grade 3/4 hypomagnesemia and hypokalemia (RR 18.29, 95 % CI 7.29–48.41, p < 0.001, and RR 3.3, 95 % CI 1.32–8.25, p = 0.011). Treatment with anti-EGFR MoAbs is associated with significantly higher risks of electrolyte disorders such as hypomagnesemia, hypomagnesemia, and hypocalcemia, especially in colorectal cancer. Rigorous monitoring and early treatment of electrolyte disorders are proposed.Electronic supplementary materialThe online version of this article (doi:10.1007/s13277-014-2983-9) contains supplementary material, which is available to authorized users.
机译:抗上皮生长因子受体单克隆抗体(抗EGFR MoAbs)在与治疗有关的电解质紊乱中的作用仍存在争议。因此,我们对已发表的随机对照试验(RCT)进行了荟萃分析,以评估所有级别和3/4级电解质紊乱事件的发生率和总体风险。我们从PubMed,EMBASE和Web of Knowledge数据库中搜索了相关的临床试验,以满足美国临床肿瘤学会和欧洲医学肿瘤学会以及ClinicalTrials.gov的议事程序。符合条件的研究包括II,III和IV期RCT。基于纳入研究的异质性,使用固定效应或随机效应模型进行了统计分析,以计算汇总发生率,相对风险(RR)和95%置信区间(CI)。这项荟萃分析共纳入来自25个RCT的16,411名患者。与抗EGFR MoAbs相关的低镁血症的全等级发生率为34.0%(95%CI 28.0-40.5%),低钾血症和低钙血症的发生率为14.5%(95%CI 8.2-24.4%)和16.8%(95%) CI 14.2–19.7%)。与大肠癌中单独化疗相比,西妥昔单抗的添加增加了3/4级低镁血症和3/4级低钾血症的风险,RR分别为7.14(95%CI 3.13–16.27,p <0.001)和2.19(95%CI 1.14– 4.23,p = 0.019)。此外,帕尼单抗病例中的结直肠癌患者更容易发生3/4级低镁血症和低钾血症(RR 18.29,95%CI 7.29-48.41,p <0.001,RR 3.3,95%CI 1.32-8.25,p = 0.011)。抗EGFR MoAbs的治疗与电解质紊乱(例如低镁血症,低镁血症和低钙血症)的风险显着较高相关,尤其是在大肠癌中。建议对电解质紊乱进行严格监控和早期治疗。电子补充材料本文的在线版本(doi:10.1007 / s13277-014-2983-9)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号